The Biotechnology week,distilled.

Viatris has entered into a definitive agreement to acquire Pacira BioSciences for $1.65 billion.

Alphabet's subsidiary Isomorphic Labs is currently in fundraising discussions aiming for a $40 billion valuation.

Ultragenyx Pharmaceutical has agreed to sell its Rare Pediatric Disease Priority Review Voucher, earned for the drug Genglycos, for $210 million.

French startup Edonia has raised €15 million in a funding round led by SWEN Blue Ocean 2, Asterion Ventures, and EIT Food to scale production of its microalgae-based protein ingredient, Edo.

Google DeepMind, Meta, and Isomorphic Labs are investing $300 million into the Chan Zuckerberg Biohub to support the development of a 'virtual cell' for biological research.

MintNeuro, a semiconductor company based in the UK and Europe, has raised $5 million in a funding round led by Odyssey Ventures.

Paris-based biotech startup Rivercell has raised $25 million in a seed funding round.

Japanese pharmaceutical company Shionogi & Co. has announced the acquisition of biotech firm IntraBio for $2 billion.

Also: 06 Oct — genengnews.com

Danaher Corporation announced on October 8, 2026, in Washington, the launch of its first AI-powered autonomous lab located at its subsidiary Abcam.

Former OpenAI and Instacart executive Fidji Simo has launched a new AI research startup called ChronicleBio.

Chinese dairy company Mengniu has launched probiotic supplement products containing its patented strain LC19, which is designed to stimulate GLP-1 hormone secretion for metabolic and weight regulation.

Nolla Health has launched a pilot program in Utah, USA, to use artificial intelligence for diagnosing acne and prescribing medication.

Canadian company Lallemand has launched a dedicated food and beverage enzyme business unit under the brand name Solyve.

Lycia Therapeutics is planning an initial public offering (IPO) to raise capital for the development of its next-generation protein degrader therapies.

The report 'BioBytes: AI-Related Deals In Q3 ‘26' by Sushmita Panda, published on October 7, 2026, provides an overview of financial transactions involving artificial intelligence within the biotechnology sector.

Caribou Biosciences, a Berkeley, California-based biotech company, announced on October 6, 2026, that it is discontinuing its two remaining therapeutic programs, vispacabtagene regedleucel (vispa-cel) and CB-011.

Researchers at the Federal Research Centre of Nutrition, Biotechnology and Food Safety in Russia conducted a randomized trial on 101 adults with metabolic dysfunction-associated steatotic liver disease.

Research presented at an aging conference in Boston indicates that GLP-1 weight-loss drugs, manufactured by Eli Lilly and Novo Nordisk, may reduce biological age by two to three years in overweight and diabetic patients.

The National Institutes of Health (N.I.H.) is launching a new initiative in December 2026 to accelerate the development of cancer vaccines.

Henri Kagan and Kensō Soai were awarded the 2026 Nobel Prize in Chemistry for their research on chemical asymmetry and homochirality.

Cerevance, a spinout from Takeda, has completed Phase 3 clinical trials for its Parkinson's disease drug candidate, solengepras.

The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for the development of optogenetics.

Henri B. Kagan and Kenso Soai have been awarded the 2026 Nobel Prize in Chemistry for their breakthroughs in asymmetric organic synthesis.

Karl Deisseroth, Peter Hegemann, and Georg Nagel were awarded the 2026 Nobel Prize in Physiology or Medicine.

Dr. Peter Hotez from Baylor College of Medicine has raised concerns regarding the unexplained death of a researcher at a Russian plague institute.

Russian authorities have concluded precautionary health measures in Irkutsk following the death of an employee at the Irkutsk Anti-Plague Institute of Siberia and the Far East.

A young worker at a Russian research institute specializing in dangerous infections died of severe pneumonia in Siberia in October 2026.

The Russian government, represented by Kremlin spokesperson Dmitry Peskov, has denied media reports regarding a second suspected case of pneumonic plague in Siberia on October 7, 2026.

A researcher at the Irkutsk Anti-Plague Institute in Siberia, Russia, died from severe pneumonia of unknown origin following a laboratory accident involving a broken test tube.

US President Donald Trump has offered assistance to Russia regarding a suspected pneumonic plague outbreak in the Irkutsk region of Siberia.

The World Health Organization (WHO) reported that no cases of plague have been registered following the death of a laboratory worker at the Irkutsk Antiplague Research Institute in Siberia, Russia.

A lab worker at the Irkutsk Anti-Plague Research Institute of Siberia and the Far East died on October 2, 2026, in Shelekhov, Russia.

The US Food and Drug Administration (FDA) is actively seeking a permanent director for its Office of Therapeutic Products, which oversees cell and gene therapy.

Nipun Juneja has been appointed as the director of investment strategy at Fresenius Ventures, the corporate venture capital arm of the German healthcare company Fresenius.

Dr. John Tsai assumed the role of global R&D head at Daiichi Sankyo in 2026.

The U.S. Department of Health and Human Services (HHS) is increasing efforts to accelerate drug development processes.

MIT Technology Review reports that the US government has frozen green card processing for Microsoft and other IT firms due to allegations of visa fraud.